Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Spepharm AG is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This workload is handled by a distinct examiner and a distinct art unit. The concentration in a distinct art unit reflects a focus for the current patent prosecution efforts. This suggests that the company is prioritizing a specific technical niche within the broader pharmaceutical landscape, as all current activity is funneled through a single examination group.
LAYLA SOROUSH is the busiest examiner for the company, currently overseeing 1 pending office action. This examiner is responsible for the company's pending office action count. Because there is a pending office action, the company's current engagement with the patent office is highly focused. The outcome of this specific action will be the primary indicator of the company's success in securing patent protection for its current innovations in the Biotechnology & Pharmaceuticals sector. Practitioners should ensure that all technical arguments are robustly supported to meet the high standards of the assigned art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18503401 | AQUEOUS COMPOSITION COMPRISING DANTROLENE | SOROUSH, LAYLA | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18503401 | AQUEOUS COMPOSITION COMPRISING DANTROLENE | SOROUSH, LAYLA | 1622 | §103DP | Final Rejection | — | Pending | Nov 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial